IPO Issue Details
Issue Price / Price Band₹603 per share (Fixed Price)
Face Value₹1 Per Share
Lot Size24 Shares per Lot
Total Issue Size2,88,75,000 shares (aggregating up to ₹1,740.49 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryOffer For Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenFri, 16 Jun 2017
Subscription CloseTue, 20 Jun 2017
Anchor AllotmentThu, 15 Jun 2017
Basis of AllotmentFri, 23 Jun 2017
Initiation of RefundsTue, 27 Jun 2017
Credit of Shares to DematWed, 28 Jun 2017
Listing DateThu, 29 Jun 2017
UPI Mandate Deadline2017-06-20
Application & Investment Details
Retail — Min (1 Lots)₹14,472 — 24 shares
Retail — Max (13 Lots)₹188,136 (13 Lots)
HNI — Min (14 Lots)₹2,02,608 — 336 shares
Pre-IPO Promoter Holding13,75,00,000 shares
Post-IPO Promoter Holding13,75,00,000 shares
About Eris Lifesciences Ltd.
Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics).In acute category, the product portfolio includes vitamins, gastroenterology, anti-infectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing.Eris Lifescience own and operate a manufacturing facility in Guwahati, Assam. They also outsource the manufacturing of certain of its products to 20 manufacturers. Eris strong sales team comprised of 1,310 marketing representatives.Eris Lifescience Strengths:• Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders• Portfolio of high volume and leading brands• Focus on metro cities and class 1 towns in India which have higher incidence of lifestyle disorders and concentration of specialists and super specialists• Multi-faceted product selection and engagement model leading to growth in prescription• Strong sales, marketing and distribution capabilities
Objects of the Issue
Eris Lifesciences Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
1 The company will not receive any proceeds from the Offer and all the proceeds will go to the Selling Shareholders.
Shareholding & Lock-in
Pre-IPO Promoter Holding
13,75,00,000 shares
Post-IPO Promoter Holding
13,75,00,000 shares
Lock-in Period (30%)July 23, 2017
Lock-in Period (50%)September 21, 2017